In the BioHarmony Drug Report Database
Tibsovo (ivosidenib) is a small molecule pharmaceutical. Ivosidenib was first approved as Tibsovo on 2018-07-20. It is used to treat myeloid leukemia acute in the USA. The pharmaceutical is active against isocitrate dehydrogenase [NADP] cytoplasmic. Tibsovo’s patents are valid until 2039-06-07 (FDA).
Image (chem structure or protein)